{"transactions":[{"id":1249052,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-24T22:52:59.000Z","date":"2025-02-24","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":0.92,"value":13800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.90 to $0.9321 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an aggregate of 120,619 shares received as a pro rata distribution from Hatteras Venture Advisors III, LLC, Hatteras Venture Advisors IV SBIC, LLC, Hatteras Venture Advisors IV, LLC and Hatteras NC Fund, LP (the \"Hatteras Entities\").  In prior reports, the reporting person reported indirect beneficial ownership of 3,545,040 shares of the Issuer's common stock held by the Hatteras Entities."}],"balance_after":176141,"source":{"system":"sec-edgar","filing":"0001415889-25-005325","document":"form4-02242025_100255.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1539029/000141588925005325/form4-02242025_100255.xml","form_type":"4"}},{"id":1471759,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-21T20:15:10.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2025, subject to the Reporting Person's continuous service as of such vesting date."}],"balance_after":45000,"derivative":{"exercise_price":1.15,"expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001415889-24-017821","document":"form4-06212024_040607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1539029/000141588924017821/form4-06212024_040607.xml","form_type":"4"}},{"id":1773799,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-25T20:34:26.000Z","date":"2023-09-25","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":0.86,"value":8600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8549 to $0.8595 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":40522,"source":{"system":"sec-edgar","filing":"0001209191-23-050480","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1539029/000120919123050480/doc4.xml","form_type":"4"}},{"id":1844903,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T20:41:43.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 22, 2024, subject to the Reporting Person's continuous service as of such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":1.31,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-23-039427","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1539029/000120919123039427/doc4.xml","form_type":"4"}},{"id":1885196,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-05-19T16:18:34.000Z","date":"2023-05-19","kind":"exercise","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001169245-23-000032","document":"wf-form4_168452749044967.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000116924523000032/wf-form4_168452749044967.xml","form_type":"4"}},{"id":1885195,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-19T16:18:34.000Z","date":"2023-05-19","kind":"exercise","planned":false,"acquired":true,"shares":3750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock."}],"balance_after":36693,"source":{"system":"sec-edgar","filing":"0001169245-23-000032","document":"wf-form4_168452749044967.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000116924523000032/wf-form4_168452749044967.xml","form_type":"4"}},{"id":2078493,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-21T21:26:40.000Z","date":"2022-12-21","kind":"purchase","acquired":true,"shares":14000,"price":1.019,"value":14266.0,"ownership":{"direct":true},"balance_after":30522,"source":{"system":"sec-edgar","filing":"0001209191-22-062338","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1539029/000120919122062338/doc4.xml","form_type":"4"}},{"id":2081188,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-20T00:41:09.000Z","date":"2022-12-15","kind":"other","acquired":true,"shares":8522,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro rata distribution, and not a purchase or sale of securities, by Hatteras Venture Partners III, LP (\"HVP III\") and Hatteras Venture Affiliates III, LP (\"HVA III\") to its general partners and limited partners without additional consideration."}],"balance_after":16522,"source":{"system":"sec-edgar","filing":"0001209191-22-062045","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1539029/000120919122062045/doc4.xml","form_type":"4"}},{"id":2081187,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-20T00:41:09.000Z","date":"2022-12-15","kind":"other","acquired":false,"shares":1406507,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro rata distribution, and not a purchase or sale of securities, by Hatteras Venture Partners III, LP (\"HVP III\") and Hatteras Venture Affiliates III, LP (\"HVA III\") to its general partners and limited partners without additional consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of Hatteras Venture Partners IV, LP (\"HVP IV\") and Hatteras NC Fund, LP (\"Hatteras NC\"). HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":3545040,"source":{"system":"sec-edgar","filing":"0001209191-22-062045","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1539029/000120919122062045/doc4.xml","form_type":"4"}},{"id":2081186,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-20T00:40:21.000Z","date":"2021-02-10","kind":"sale","acquired":false,"shares":32873,"price":4.43,"value":145627.39,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holders of the securities on March 16, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"Consists of (i) 447 shares sold by Hatteras NC Fund, LP (\"Hatteras NC\"), (ii) 21,095 shares sold by Hatteras Venture Partners III, LP (\"HVP III\"), (iii) 1,916 shares sold by Hatteras Venture Affiliates III, LP (\"HVA III\") and (iv) 9,415 shares sold by Hatteras Venture Partners IV SBIC, LP (\"HVP IV SBIC\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $4.40 to $4.50, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The original Form 4 inadvertently misstated the total number of shares.  This reflect the accurate number of shares beneficially owned."}],"balance_after":4951547,"source":{"system":"sec-edgar","filing":"0001209191-22-062044","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1539029/000120919122062044/doc4a.xml","form_type":"4/A","original_submission_date":"2021-02-10"}},{"id":2221828,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-24T20:21:51.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 22, 2023."}],"balance_after":30000,"derivative":{"exercise_price":1.62,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-22-039220","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1539029/000120919122039220/doc4.xml","form_type":"4"}},{"id":2262228,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-05-20T16:46:12.000Z","date":"2022-05-19","kind":"grant","acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs shall vest and be delivered to the Reporting Person on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs shall vest and be delivered to the Reporting Person on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date."}],"balance_after":3750,"derivative":{"underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001169245-22-000065","document":"wf-form4_165307954416772.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000116924522000065/wf-form4_165307954416772.xml","form_type":"4"}},{"id":2262227,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-employee Director Stock Option (right to buy)","published_at":"2022-05-20T16:46:12.000Z","date":"2022-05-19","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date."}],"balance_after":17500,"derivative":{"exercise_price":0.8419,"expiration_date":"2032-05-18","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001169245-22-000065","document":"wf-form4_165307954416772.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000116924522000065/wf-form4_165307954416772.xml","form_type":"4"}},{"id":2267367,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-17T21:06:52.000Z","date":"2022-05-17","kind":"purchase","acquired":true,"shares":14893,"price":2.9671,"value":44189.0203,"ownership":{"direct":false,"nature":"By Hatteras Venture Partners VI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.76 to $3.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Hatteras Venture Partners VI, L.P. (\"Hatteras VI\"). Hatteras Venture Advisors VI, LLC (\"HVA VI\") is the general partner of Hatteras VI. The Reporting Person is a managing member of HVA VI and disclaims beneficial ownership of the shares held by Hatteras VI except to the extent of his pecuniary interest therein, if any."}],"balance_after":1556030,"source":{"system":"sec-edgar","filing":"0000899243-22-018491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1592380/000089924322018491/doc4.xml","form_type":"4"}},{"id":2267366,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-17T21:06:52.000Z","date":"2022-05-16","kind":"purchase","acquired":true,"shares":21802,"price":2.7622,"value":60221.4844,"ownership":{"direct":false,"nature":"By Hatteras Venture Partners VI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.50 to $2.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Hatteras Venture Partners VI, L.P. (\"Hatteras VI\"). Hatteras Venture Advisors VI, LLC (\"HVA VI\") is the general partner of Hatteras VI. The Reporting Person is a managing member of HVA VI and disclaims beneficial ownership of the shares held by Hatteras VI except to the extent of his pecuniary interest therein, if any."}],"balance_after":1541137,"source":{"system":"sec-edgar","filing":"0000899243-22-018491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1592380/000089924322018491/doc4.xml","form_type":"4"}},{"id":2316298,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-28T16:44:36.000Z","date":"2022-03-28","kind":"purchase","acquired":true,"shares":3000,"price":7.2014,"value":21604.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $6.9163 to $7.469, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0000899243-22-012485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1592380/000089924322012485/doc4.xml","form_type":"4"}},{"id":2437406,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2022-01-11T21:20:50.000Z","date":"2022-01-11","kind":"exercise","acquired":false,"shares":926506,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Partners VI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") on a one-for-2.7732 basis upon the closing of the Issuer's initial public offering on January 1, 2022 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") on a one-for-2.7732 basis upon the closing of the Issuer's initial public offering on January 1, 2022 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") on a one-for-2.7732 basis upon the closing of the Issuer's initial public offering on January 1, 2022 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Hatteras Venture Partners VI, L.P. (\"Hatteras VI\"). Hatteras Venture Advisors VI, LLC (\"HVA VI\") is the general partner of Hatteras VI. The Reporting Person is a managing member of HVA VI and disclaims beneficial ownership of the shares held by Hatteras VI except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":334092},"source":{"system":"sec-edgar","filing":"0000899243-22-001658","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1592380/000089924322001658/doc4.xml","form_type":"4"}},{"id":2437405,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2022-01-11T21:20:50.000Z","date":"2022-01-11","kind":"exercise","acquired":false,"shares":2552021,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Partners VI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") on a one-for-2.7732 basis upon the closing of the Issuer's initial public offering on January 1, 2022 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") on a one-for-2.7732 basis upon the closing of the Issuer's initial public offering on January 1, 2022 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") on a one-for-2.7732 basis upon the closing of the Issuer's initial public offering on January 1, 2022 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Hatteras Venture Partners VI, L.P. (\"Hatteras VI\"). Hatteras Venture Advisors VI, LLC (\"HVA VI\") is the general partner of Hatteras VI. The Reporting Person is a managing member of HVA VI and disclaims beneficial ownership of the shares held by Hatteras VI except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":920243},"source":{"system":"sec-edgar","filing":"0000899243-22-001658","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1592380/000089924322001658/doc4.xml","form_type":"4"}},{"id":2437404,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-11T21:20:50.000Z","date":"2022-01-11","kind":"purchase","acquired":true,"shares":265000,"price":14,"value":3710000.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Partners VI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On January 11, 2022, Hatteras VI purchased 265,000 shares of Common Stock of the Issuer at a price of $14.00 per share pursuant to an underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Hatteras Venture Partners VI, L.P. (\"Hatteras VI\"). Hatteras Venture Advisors VI, LLC (\"HVA VI\") is the general partner of Hatteras VI. The Reporting Person is a managing member of HVA VI and disclaims beneficial ownership of the shares held by Hatteras VI except to the extent of his pecuniary interest therein, if any."}],"balance_after":1519335,"source":{"system":"sec-edgar","filing":"0000899243-22-001658","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1592380/000089924322001658/doc4.xml","form_type":"4"}},{"id":2437403,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-11T21:20:50.000Z","date":"2022-01-11","kind":"exercise","acquired":true,"shares":1254335,"ownership":{"direct":false,"nature":"By Hatteras Venture Partners VI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") on a one-for-2.7732 basis upon the closing of the Issuer's initial public offering on January 1, 2022 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Hatteras Venture Partners VI, L.P. (\"Hatteras VI\"). Hatteras Venture Advisors VI, LLC (\"HVA VI\") is the general partner of Hatteras VI. The Reporting Person is a managing member of HVA VI and disclaims beneficial ownership of the shares held by Hatteras VI except to the extent of his pecuniary interest therein, if any."}],"balance_after":1254335,"source":{"system":"sec-edgar","filing":"0000899243-22-001658","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1592380/000089924322001658/doc4.xml","form_type":"4"}},{"id":2598299,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-18T18:07:19.000Z","date":"2021-08-18","kind":"purchase","acquired":true,"shares":10000,"price":3,"value":30000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.97 to $3.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding he number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4."}],"balance_after":32943,"source":{"system":"sec-edgar","filing":"0001169245-21-000080","document":"wf-form4_162932441876756.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000116924521000080/wf-form4_162932441876756.xml","form_type":"4"}},{"id":2671369,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-11T21:33:26.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 10, 2022."}],"balance_after":25000,"derivative":{"exercise_price":3.11,"expiration_date":"2031-06-09","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-21-039951","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1539029/000120919121039951/doc4.xml","form_type":"4"}},{"id":2681302,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-employee Director Stock Option (right to buy)","published_at":"2021-06-04T18:03:57.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest upon the earlier of the one year anniversary of the grant date or the 2022 annual meeting, subject to the reporting person's continuous service through each such date"}],"balance_after":14000,"derivative":{"exercise_price":3.53,"expiration_date":"2031-06-03","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001169245-21-000059","document":"wf-form4_162284422309457.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000116924521000059/wf-form4_162284422309457.xml","form_type":"4"}},{"id":2862498,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-12T22:22:47.000Z","date":"2021-02-10","kind":"sale","acquired":false,"shares":32873,"price":4.43,"value":145627.39,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holders of the securities on March 16, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"Consists of (i) 447 shares sold by Hatteras NC Fund, LP (\"Hatteras NC\"), (ii) 21,095 shares sold by Hatteras Venture Partners III, LP (\"HVP III\"), (iii) 1,916 shares sold by Hatteras Venture Affiliates III, LP (\"HVA III\") and (iv) 9,415 shares sold by Hatteras Venture Partners IV SBIC, LP (\"HVP IV SBIC\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $4.40 to $4.50, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of HVP IV and Hatteras NC. HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":3433521,"source":{"system":"sec-edgar","filing":"0001209191-21-010259","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1539029/000120919121010259/doc4.xml","form_type":"4"}},{"id":2968414,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-24T16:04:05.000Z","date":"2020-11-24","kind":"purchase","acquired":true,"shares":2000,"price":3.5,"value":7000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.48 to $3.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":22943,"source":{"system":"sec-edgar","filing":"0001169245-20-000107","document":"wf-form4_160625183199754.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000116924520000107/wf-form4_160625183199754.xml","form_type":"4"}},{"id":2968413,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-24T16:04:05.000Z","date":"2020-11-23","kind":"purchase","acquired":true,"shares":3000,"price":3.67,"value":11010.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.66 to $3.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4"}],"balance_after":20943,"source":{"system":"sec-edgar","filing":"0001169245-20-000107","document":"wf-form4_160625183199754.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000116924520000107/wf-form4_160625183199754.xml","form_type":"4"}},{"id":2975669,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-18T19:19:42.000Z","date":"2020-11-16","kind":"other","acquired":true,"shares":10586,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Catalysta Ventures, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this form represent a pro rata distribution, and not a purchase or sale of securities, by Hatteras Venture Partners I, LP to its respective general and limited partners or members without consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person is a manager of Catalysta and may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta. The reporting person disclaims beneficial ownership of the securities held by Catalysta except to the extent of his pecuniary interest therein."}],"balance_after":15432,"source":{"system":"sec-edgar","filing":"0001209191-20-059250","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919120059250/doc4.xml","form_type":"4"}},{"id":2975668,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-18T19:19:42.000Z","date":"2020-11-16","kind":"other","acquired":true,"shares":2144,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this form represent a pro rata distribution, and not a purchase or sale of securities, by Hatteras Venture Partners I, LP to its respective general and limited partners or members without consideration."}],"balance_after":17943,"source":{"system":"sec-edgar","filing":"0001209191-20-059250","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919120059250/doc4.xml","form_type":"4"}},{"id":2975667,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-18T19:19:42.000Z","date":"2020-11-16","kind":"other","acquired":false,"shares":52397,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Partners I, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this form represent a pro rata distribution, and not a purchase or sale of securities, by Hatteras Venture Partners I, LP to its respective general and limited partners or members without consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Catalysta Ventures, LLC (\"Catalysta\") is the general partner of Hatteras Venture Partners I, LP (\"HVP I\"). The securities held directly by HVP I are indirectly held by Catalysta. The reporting person is a manager of Catalysta and may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The reporting person disclaims beneficial ownership of the securities held by Catalysta and HVP I except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-059250","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919120059250/doc4.xml","form_type":"4"}},{"id":3103991,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-19T20:41:20.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 18, 2021."}],"balance_after":25000,"derivative":{"exercise_price":2,"expiration_date":"2030-06-17","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-20-037955","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1539029/000120919120037955/doc4.xml","form_type":"4"}},{"id":3120778,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-employee Director Stock Option (right to buy)","published_at":"2020-06-05T19:02:21.000Z","date":"2020-06-03","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest upon the earlier of the one year anniversary of the grant date or the 2021 annual meeting, subject to the reporting person's continuous service through each such date"}],"balance_after":16000,"derivative":{"exercise_price":4.86,"expiration_date":"2030-06-03","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001169245-20-000069","document":"wf-form4_159139812354604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000116924520000069/wf-form4_159139812354604.xml","form_type":"4"}},{"id":3358465,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-11-26T21:33:37.000Z","date":"2019-11-22","kind":"grant","acquired":true,"shares":1518026,"price":1.054,"value":1599999.404,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of Hatteras Venture Partners III, LP (\"HVP III\") and Hatteras Venture Affiliates III, LP (\"HVA III\"); (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of Hatteras Venture Partners IV SBIC, LP (\"HVP IV SBIC\"); and (iii) Hatteras Venture Advisors IV, LLC, the general partner of Hatteras Venture Partners IV, LP (\"HVP IV\") and Hatteras NC Fund, LP (\"Hatteras NC\"). HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":4984420,"source":{"system":"sec-edgar","filing":"0001209191-19-058129","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1539029/000120919119058129/doc4.xml","form_type":"4"}},{"id":3468619,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-07-03T16:28:36.000Z","date":"2019-07-01","kind":"sale","acquired":false,"shares":459,"price":14,"value":6426.0,"ownership":{"direct":false,"nature":"By Venture Capital Multiplier Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by HVP III, HV Affiliates, HVP I and Multiplier Fund (each as defined in Footnotes (4), (5) and (6) below)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold on multiple transactions at prices ranging from $14.00 to $14.01. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Hatteras Venture Advisors V, LLC (\"HVA V\") is the general partner of Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by Multiplier Fund are indirectly held by HVA V. The reporting person is a manager of HVA V and may be deemed to share voting and dispositive power with regard to the securities held by Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":415959,"source":{"system":"sec-edgar","filing":"0001209191-19-041112","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919119041112/doc4.xml","form_type":"4"}},{"id":3468618,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-07-03T16:28:36.000Z","date":"2019-07-01","kind":"sale","acquired":false,"shares":255,"price":14,"value":3570.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Partners I, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by HVP III, HV Affiliates, HVP I and Multiplier Fund (each as defined in Footnotes (4), (5) and (6) below)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold on multiple transactions at prices ranging from $14.00 to $14.01. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amount has been adjusted to correct a de minimis clerical error in previous filings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Catalysta Ventures, LLC (\"Catalysta\") is the general partner of Hatteras Venture Partners I, LP (\"HVP I\"). The securities held directly by HVP I are indirectly held by Catalysta. The reporting person is a manager of Catalysta and may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The reporting person disclaims beneficial ownership of the securities held by Catalysta and HVP I except to the extent of his pecuniary interest therein."}],"balance_after":52397,"source":{"system":"sec-edgar","filing":"0001209191-19-041112","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919119041112/doc4.xml","form_type":"4"}},{"id":3468617,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-07-03T16:28:36.000Z","date":"2019-07-01","kind":"sale","acquired":false,"shares":180,"price":14,"value":2520.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Affiliates III, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by HVP III, HV Affiliates, HVP I and Multiplier Fund (each as defined in Footnotes (4), (5) and (6) below)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold on multiple transactions at prices ranging from $14.00 to $14.01. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amount has been adjusted to correct a de minimis clerical error in previous filings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\") and Hatteras Venture Affiliates III, LP (\"HV Affiliates\"). The securities held directly by HVP III and HV Affiliates are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III and HV Affiliates except to the extent of his pecuniary interest therein."}],"balance_after":162890,"source":{"system":"sec-edgar","filing":"0001209191-19-041112","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919119041112/doc4.xml","form_type":"4"}},{"id":3468616,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-07-03T16:28:36.000Z","date":"2019-07-01","kind":"sale","acquired":false,"shares":2014,"price":14,"value":28196.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Partners III, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by HVP III, HV Affiliates, HVP I and Multiplier Fund (each as defined in Footnotes (4), (5) and (6) below)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold on multiple transactions at prices ranging from $14.00 to $14.01. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amount has been adjusted to correct a de minimis clerical error in previous filings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\") and Hatteras Venture Affiliates III, LP (\"HV Affiliates\"). The securities held directly by HVP III and HV Affiliates are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III and HV Affiliates except to the extent of his pecuniary interest therein."}],"balance_after":1818638,"source":{"system":"sec-edgar","filing":"0001209191-19-041112","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919119041112/doc4.xml","form_type":"4"}},{"id":3479783,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-24T20:29:44.000Z","date":"2019-06-20","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2020."}],"balance_after":20000,"derivative":{"exercise_price":1.07,"expiration_date":"2029-06-19","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-19-038772","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1539029/000120919119038772/doc4.xml","form_type":"4"}},{"id":3482950,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-20T19:09:52.000Z","date":"2019-06-18","kind":"sale","acquired":false,"shares":63,"price":14,"value":882.0,"ownership":{"direct":false,"nature":"By Venture Capital Multiplier Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by HVP III, HV Affiliates, HVP I and Multiplier Fund (each as defined in Footnotes (2) and (4) below)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Hatteras Venture Advisors V, LLC (\"HVA V\") is the general partner of Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by Multiplier Fund are indirectly held by HVA V. The reporting person is a manager of HVA V and may be deemed to share voting and dispositive power with regard to the securities held by Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":416418,"source":{"system":"sec-edgar","filing":"0001209191-19-038324","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919119038324/doc4.xml","form_type":"4"}},{"id":3482949,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-20T19:09:52.000Z","date":"2019-06-18","kind":"sale","acquired":false,"shares":35,"price":14,"value":490.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Partners I, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by HVP III, HV Affiliates, HVP I and Multiplier Fund (each as defined in Footnotes (2) and (4) below)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Catalysta Ventures, LLC (\"Catalysta\") is the general partner of Hatteras Venture Partners I, LP (\"HVP I\"). The securities held directly by HVP I are indirectly held by Catalysta. The reporting person is a manager of Catalysta and may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The reporting person disclaims beneficial ownership of the securities held by Catalysta and HVP I except to the extent of his pecuniary interest therein."}],"balance_after":52655,"source":{"system":"sec-edgar","filing":"0001209191-19-038324","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919119038324/doc4.xml","form_type":"4"}},{"id":3482948,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-20T19:09:52.000Z","date":"2019-06-18","kind":"sale","acquired":false,"shares":25,"price":14,"value":350.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Affiliates III, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by HVP III, HV Affiliates, HVP I and Multiplier Fund (each as defined in Footnotes (2) and (4) below)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\") and Hatteras Venture Affiliates III, LP (\"HV Affiliates\"). The securities held directly by HVP III and HV Affiliates are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III and HV Affiliates except to the extent of his pecuniary interest therein."}],"balance_after":163074,"source":{"system":"sec-edgar","filing":"0001209191-19-038324","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919119038324/doc4.xml","form_type":"4"}},{"id":3482947,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-20T19:09:52.000Z","date":"2019-06-18","kind":"sale","acquired":false,"shares":277,"price":14,"value":3878.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Partners III, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by HVP III, HV Affiliates, HVP I and Multiplier Fund (each as defined in Footnotes (2) and (4) below)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\") and Hatteras Venture Affiliates III, LP (\"HV Affiliates\"). The securities held directly by HVP III and HV Affiliates are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III and HV Affiliates except to the extent of his pecuniary interest therein."}],"balance_after":1820656,"source":{"system":"sec-edgar","filing":"0001209191-19-038324","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919119038324/doc4.xml","form_type":"4"}},{"id":3530102,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Non-employee Director Stock Option (right to buy)","published_at":"2019-05-13T16:35:33.000Z","date":"2019-05-09","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest upon the earlier of the one year anniversary of the grant date or the date of the 2020 annual meeting, subject to the reporting person's continuous service through each such date."}],"balance_after":11000,"derivative":{"exercise_price":13.23,"expiration_date":"2029-05-09","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001209191-19-029351","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919119029351/doc4.xml","form_type":"4"}},{"id":3623537,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-03-01T17:02:15.000Z","date":"2019-02-27","kind":"grant","acquired":true,"shares":36000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in equal monthly installments over 36 months from October 17, 2018, subject to the reporting person's continued service through each such date."}],"balance_after":36000,"derivative":{"exercise_price":3.15,"expiration_date":"2029-02-27","underlying":"Common Stock","underlying_shares":36000},"source":{"system":"sec-edgar","filing":"0001209191-19-015076","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919119015076/doc4.xml","form_type":"4"}},{"id":3740751,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-12-06T22:41:29.000Z","date":"2018-12-06","kind":"purchase","acquired":true,"shares":8000,"price":1.36,"value":10880.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $1.3398 to $1.393, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":8000,"source":{"system":"sec-edgar","filing":"0001209191-18-061355","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1539029/000120919118061355/doc4.xml","form_type":"4"}},{"id":3741703,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-12-06T09:15:16.000Z","date":"2018-12-04","kind":"purchase","acquired":true,"shares":4000,"price":3.13,"value":12520.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.98 to $3.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4."}],"balance_after":15799,"source":{"system":"sec-edgar","filing":"0001209191-18-061125","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118061125/doc4.xml","form_type":"4"}},{"id":3784167,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"exercise","acquired":false,"shares":226061,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Venture Capital Multiplier Fund"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":226061},"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":38,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784166,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"exercise","acquired":false,"shares":24709,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Affiliates III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":24709},"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":37,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784165,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"exercise","acquired":false,"shares":272107,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Partners III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":272107},"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":36,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784164,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"exercise","acquired":false,"shares":40420,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Venture Capital Multiplier Fund"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":40420},"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":35,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784163,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"exercise","acquired":false,"shares":13558,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Affiliates III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13558},"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":34,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784162,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"exercise","acquired":false,"shares":149320,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Partners III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":149320},"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":33,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784161,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"exercise","acquired":false,"shares":94874,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Affiliates III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":94874},"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":32,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784160,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"exercise","acquired":false,"shares":1044764,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Partners III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1044764},"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":31,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784159,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series AA Preferred Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"exercise","acquired":false,"shares":13609,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Affiliates III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13609},"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784158,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series AA Preferred Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"exercise","acquired":false,"shares":174699,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Partners III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":174699},"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784157,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1 Preferred Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"exercise","acquired":false,"shares":4846,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Catalysta Ventures, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Catalysta Ventures, LLC (\"Catalysta\") is the general partner of Hatteras Venture Partners I, LP (\"HVP I\"). The securities held directly by HVP I are indirectly held by Catalysta. The reporting person is a manager of Catalysta and may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The reporting person disclaims beneficial ownership of the securities held by Catalysta and HVP I except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4846},"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784156,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1 Preferred Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"exercise","acquired":false,"shares":3862,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Affiliates III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3862},"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784155,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1 Preferred Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"exercise","acquired":false,"shares":42530,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Partners III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":42530},"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784154,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series 1 Preferred Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"exercise","acquired":false,"shares":52690,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Partners I, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Catalysta Ventures, LLC (\"Catalysta\") is the general partner of Hatteras Venture Partners I, LP (\"HVP I\"). The securities held directly by HVP I are indirectly held by Catalysta. The reporting person is a manager of Catalysta and may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The reporting person disclaims beneficial ownership of the securities held by Catalysta and HVP I except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":52690},"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784153,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"sale","acquired":false,"shares":994,"price":5,"value":4970.0,"ownership":{"direct":false,"nature":"By Venture Capital Multiplier Fund"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":40420,"derivative":{"underlying":"Common Stock","underlying_shares":994},"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784152,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"exercise","acquired":true,"shares":41414,"price":0.12,"value":4969.68,"ownership":{"direct":false,"nature":"By Venture Capital Multiplier Fund"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":41414,"derivative":{"underlying":"Common Stock","underlying_shares":41414},"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784151,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Series C-1 Preferred Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"exercise","acquired":false,"shares":41414,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Venture Capital Multiplier Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":0.12,"underlying":"Series C-1 Preferred Stock","underlying_shares":41414},"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784150,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"sale","acquired":false,"shares":104,"price":5,"value":520.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Affiliates III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":13558,"derivative":{"underlying":"Common Stock","underlying_shares":104},"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784149,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"exercise","acquired":true,"shares":4309,"price":0.12,"value":517.08,"ownership":{"direct":false,"nature":"By Hatteras Venture Affiliates III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":13662,"derivative":{"underlying":"Common Stock","underlying_shares":4309},"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784148,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Series C-1 Preferred Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"exercise","acquired":false,"shares":4309,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Affiliates III, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":0.12,"underlying":"Series C-1 Preferred Stock","underlying_shares":4309},"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784147,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"sale","acquired":false,"shares":1139,"price":5,"value":5695.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Partners III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":149320,"derivative":{"underlying":"Common Stock","underlying_shares":1139},"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784146,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"exercise","acquired":true,"shares":47458,"price":0.12,"value":5694.96,"ownership":{"direct":false,"nature":"By Hatteras Venture Partners III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":150459,"derivative":{"underlying":"Common Stock","underlying_shares":47458},"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784145,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Series C-1 Preferred Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"exercise","acquired":false,"shares":47458,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Partners III, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":0.12,"underlying":"Series C-1 Preferred Stock","underlying_shares":47458},"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784144,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"sale","acquired":false,"shares":42,"price":5,"value":210.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Affiliates III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":94874,"derivative":{"underlying":"Common Stock","underlying_shares":42},"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784143,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"exercise","acquired":true,"shares":1731,"price":0.12,"value":207.72,"ownership":{"direct":false,"nature":"By Hatteras Venture Affiliates III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":94916,"derivative":{"underlying":"Common Stock","underlying_shares":1731},"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784142,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Series B Preferred Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"exercise","acquired":false,"shares":1731,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Affiliates III, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":0.12,"underlying":"Series B Preferred Stock","underlying_shares":1731},"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784141,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"sale","acquired":false,"shares":458,"price":5,"value":2290.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Partners III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":1044764,"derivative":{"underlying":"Common Stock","underlying_shares":458},"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784140,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"exercise","acquired":true,"shares":19061,"price":0.12,"value":2287.32,"ownership":{"direct":false,"nature":"By Hatteras Venture Partners III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":1045222,"derivative":{"underlying":"Common Stock","underlying_shares":19061},"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784139,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Series B Preferred Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"exercise","acquired":false,"shares":19061,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Partners III, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":0.12,"underlying":"Series B Preferred Stock","underlying_shares":19061},"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784138,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"purchase","acquired":true,"shares":150000,"price":5,"value":750000.0,"ownership":{"direct":false,"nature":"By Venture Capital Multiplier Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":416481,"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784137,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"exercise","acquired":true,"shares":266481,"ownership":{"direct":false,"nature":"By Venture Capital Multiplier Fund"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":266481,"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784136,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"exercise","acquired":true,"shares":4846,"ownership":{"direct":false,"nature":"By Catalysta Ventures, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Catalysta Ventures, LLC (\"Catalysta\") is the general partner of Hatteras Venture Partners I, LP (\"HVP I\"). The securities held directly by HVP I are indirectly held by Catalysta. The reporting person is a manager of Catalysta and may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The reporting person disclaims beneficial ownership of the securities held by Catalysta and HVP I except to the extent of his pecuniary interest therein."}],"balance_after":4846,"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784135,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"purchase","acquired":true,"shares":12487,"price":5,"value":62435.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Affiliates III, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":163099,"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784134,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"exercise","acquired":true,"shares":150612,"ownership":{"direct":false,"nature":"By Hatteras Venture Affiliates III, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":150612,"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784133,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"purchase","acquired":true,"shares":137513,"price":5,"value":687565.0,"ownership":{"direct":false,"nature":"By Hatteras Venture Partners III, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":1820933,"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784132,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"exercise","acquired":true,"shares":1683420,"ownership":{"direct":false,"nature":"By Hatteras Venture Partners III, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Hatteras Venture Advisors III, LLC (\"HVA III\") is the general partner of Hatteras Venture Partners III, LP (\"HVP III\"), Hatteras Venture Affiliates III, LP (\"HV Affiliates\") and Venture Capital Multiplier Fund (\"Multiplier Fund\"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein."}],"balance_after":1683420,"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3784131,"issuer":{"id":113305,"kind":"organization","name":"PhaseBio Pharmaceuticals Inc","symbol":"PHAS"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-24T16:19:45.000Z","date":"2018-10-22","kind":"exercise","acquired":true,"shares":52690,"ownership":{"direct":false,"nature":"By Hatteras Venture Partners I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Catalysta Ventures, LLC (\"Catalysta\") is the general partner of Hatteras Venture Partners I, LP (\"HVP I\"). The securities held directly by HVP I are indirectly held by Catalysta. The reporting person is a manager of Catalysta and may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The reporting person disclaims beneficial ownership of the securities held by Catalysta and HVP I except to the extent of his pecuniary interest therein."}],"balance_after":52690,"source":{"system":"sec-edgar","filing":"0001209191-18-056051","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1169245/000120919118056051/doc4.xml","form_type":"4"}},{"id":3885848,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-21T21:23:00.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2019."}],"balance_after":11250,"derivative":{"exercise_price":10.74,"expiration_date":"2028-06-19","underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0001209191-18-038988","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1539029/000120919118038988/doc4.xml","form_type":"4"}},{"id":3910878,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":166141,"kind":"organization","name":"Hatteras Venture Advisors IV SBIC, LLC","position":2,"cik":"0001675236","reported_name":"Hatteras Venture Advisors IV SBIC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":166142,"kind":"organization","name":"Hatteras Venture Partners IV SBIC, LP","position":3,"cik":"0001675232","reported_name":"Hatteras Venture Partners IV SBIC, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16884,"kind":"person","name":"INGRAM ROBERT ALEXANDER","position":4,"cik":"0001219890","reported_name":"INGRAM ROBERT ALEXANDER","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162814,"kind":"person","name":"Crumpler John","position":5,"cik":"0001674107","reported_name":"Crumpler John","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112297,"kind":"person","name":"LEE KENNETH B JR","position":6,"cik":"0001208570","reported_name":"LEE KENNETH B JR","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162813,"kind":"person","name":"Reed Douglas MD","position":7,"cik":"0001291262","reported_name":"Reed Douglas MD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-01T18:22:00.000Z","date":"2018-05-30","kind":"sale","acquired":false,"shares":41710,"price":48,"value":2002080.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Following the reported transaction, in which none of the reportable securities owned directly by Hatteras Venture Advisors V, LLC (\"HVA V\") were sold, 995 shares of the reportable securities are owned directly by HVA V. The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a \"Managing Member\" and collectively, the \"Managing Members\"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Following the reported transaction, 168,754 shares of the reportable securities are owned directly by Hatteras NC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Following the reported transaction, in which none of the reportable securities owned directly by HVP IV were sold, 3,067,962 shares of the reportable securities are owned directly by HVP IV."}],"balance_after":3237711,"source":{"system":"sec-edgar","filing":"0001209191-18-034839","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674107/000120919118034839/doc4.xml","form_type":"4"}},{"id":3910877,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":166141,"kind":"organization","name":"Hatteras Venture Advisors IV SBIC, LLC","position":2,"cik":"0001675236","reported_name":"Hatteras Venture Advisors IV SBIC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":166142,"kind":"organization","name":"Hatteras Venture Partners IV SBIC, LP","position":3,"cik":"0001675232","reported_name":"Hatteras Venture Partners IV SBIC, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16884,"kind":"person","name":"INGRAM ROBERT ALEXANDER","position":4,"cik":"0001219890","reported_name":"INGRAM ROBERT ALEXANDER","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162814,"kind":"person","name":"Crumpler John","position":5,"cik":"0001674107","reported_name":"Crumpler John","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112297,"kind":"person","name":"LEE KENNETH B JR","position":6,"cik":"0001208570","reported_name":"LEE KENNETH B JR","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162813,"kind":"person","name":"Reed Douglas MD","position":7,"cik":"0001291262","reported_name":"Reed Douglas MD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-01T18:22:00.000Z","date":"2018-05-30","kind":"sale","acquired":false,"shares":758290,"price":48,"value":36397920.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Following the reported transaction, in which none of the reportable securities owned directly by Hatteras Venture Advisors V, LLC (\"HVA V\") were sold, 995 shares of the reportable securities are owned directly by HVA V. The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a \"Managing Member\" and collectively, the \"Managing Members\"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Following the reported transaction, 3,067,962 shares of the reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP (\"HVP IV\"). Hatteras Venture Advisors IV SBIC, LLC (\"HVA IV SBIC\") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a \"GP Managing Member\" and collectively, the \"GP Managing Members\"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Following the reported transaction, in which none of the reportable securities owned directly by Hatteras NC Fund, LP (\"Hatteras NC\") were sold, 210,464 shares of the reportable securities are owned directly by Hatteras NC. Hatteras Venture Advisors IV, LLC (\"HVA IV\") is the general partner of Hatteras NC. The securities directly held by Hatteras NC are indirectly held by the individual managing members of HVA IV (each, a \"HVA IV Managing Member\"). The HVA IV Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The HVA IV Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each HVA IV Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any HVA IV Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein."}],"balance_after":3279421,"source":{"system":"sec-edgar","filing":"0001209191-18-034839","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674107/000120919118034839/doc4.xml","form_type":"4"}},{"id":3920693,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":166141,"kind":"organization","name":"Hatteras Venture Advisors IV SBIC, LLC","position":2,"cik":"0001675236","reported_name":"Hatteras Venture Advisors IV SBIC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":166142,"kind":"organization","name":"Hatteras Venture Partners IV SBIC, LP","position":3,"cik":"0001675232","reported_name":"Hatteras Venture Partners IV SBIC, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16884,"kind":"person","name":"INGRAM ROBERT ALEXANDER","position":4,"cik":"0001219890","reported_name":"INGRAM ROBERT ALEXANDER","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162814,"kind":"person","name":"Crumpler John","position":5,"cik":"0001674107","reported_name":"Crumpler John","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112297,"kind":"person","name":"LEE KENNETH B JR","position":6,"cik":"0001208570","reported_name":"LEE KENNETH B JR","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162813,"kind":"person","name":"Reed Douglas MD","position":7,"cik":"0001291262","reported_name":"Reed Douglas MD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-23T20:46:07.000Z","date":"2018-05-23","kind":"sale","acquired":false,"shares":26,"price":50.5,"value":1313.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC (\"HVA V\"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a \"Managing Member\" and collectively, the \"Managing Members\"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"Following the reported transaction, 3,826,252 shares of the reportable securities are owned directly by HVP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"Following the reported transaction, 210,464 shares of the reportable securities are owned directly by Hatteras NC."}],"balance_after":4037711,"source":{"system":"sec-edgar","filing":"0001209191-18-032789","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1674107/000120919118032789/doc4.xml","form_type":"4"}},{"id":3920692,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":166141,"kind":"organization","name":"Hatteras Venture Advisors IV SBIC, LLC","position":2,"cik":"0001675236","reported_name":"Hatteras Venture Advisors IV SBIC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":166142,"kind":"organization","name":"Hatteras Venture Partners IV SBIC, LP","position":3,"cik":"0001675232","reported_name":"Hatteras Venture Partners IV SBIC, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16884,"kind":"person","name":"INGRAM ROBERT ALEXANDER","position":4,"cik":"0001219890","reported_name":"INGRAM ROBERT ALEXANDER","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162814,"kind":"person","name":"Crumpler John","position":5,"cik":"0001674107","reported_name":"Crumpler John","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112297,"kind":"person","name":"LEE KENNETH B JR","position":6,"cik":"0001208570","reported_name":"LEE KENNETH B JR","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162813,"kind":"person","name":"Reed Douglas MD","position":7,"cik":"0001291262","reported_name":"Reed Douglas MD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-23T20:46:07.000Z","date":"2018-05-23","kind":"sale","acquired":false,"shares":474,"price":50.5,"value":23937.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC (\"HVA V\"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a \"Managing Member\" and collectively, the \"Managing Members\"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"Following the reported transaction, 210,490 shares of the reportable securities are owned directly by Hatteras NC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"Following the reported transaction, 3,826,252 shares of the reportable securities are owned directly by HVP IV."}],"balance_after":4037737,"source":{"system":"sec-edgar","filing":"0001209191-18-032789","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1674107/000120919118032789/doc4.xml","form_type":"4"}},{"id":3920691,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":166141,"kind":"organization","name":"Hatteras Venture Advisors IV SBIC, LLC","position":2,"cik":"0001675236","reported_name":"Hatteras Venture Advisors IV SBIC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":166142,"kind":"organization","name":"Hatteras Venture Partners IV SBIC, LP","position":3,"cik":"0001675232","reported_name":"Hatteras Venture Partners IV SBIC, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16884,"kind":"person","name":"INGRAM ROBERT ALEXANDER","position":4,"cik":"0001219890","reported_name":"INGRAM ROBERT ALEXANDER","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162814,"kind":"person","name":"Crumpler John","position":5,"cik":"0001674107","reported_name":"Crumpler John","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112297,"kind":"person","name":"LEE KENNETH B JR","position":6,"cik":"0001208570","reported_name":"LEE KENNETH B JR","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162813,"kind":"person","name":"Reed Douglas MD","position":7,"cik":"0001291262","reported_name":"Reed Douglas MD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-23T20:46:07.000Z","date":"2018-05-22","kind":"sale","acquired":false,"shares":308,"price":50.6851,"value":15611.0108,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price represents the weighted average price with a low of $50.50 and a high of $51.25."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC (\"HVA V\"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a \"Managing Member\" and collectively, the \"Managing Members\"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Following the reported transaction, 3,826,726 shares of the reportable securities are owned directly by HVP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"Following the reported transaction, 210,490 shares of the reportable securities are owned directly by Hatteras NC."}],"balance_after":4038211,"source":{"system":"sec-edgar","filing":"0001209191-18-032789","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1674107/000120919118032789/doc4.xml","form_type":"4"}},{"id":3920690,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":166141,"kind":"organization","name":"Hatteras Venture Advisors IV SBIC, LLC","position":2,"cik":"0001675236","reported_name":"Hatteras Venture Advisors IV SBIC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":166142,"kind":"organization","name":"Hatteras Venture Partners IV SBIC, LP","position":3,"cik":"0001675232","reported_name":"Hatteras Venture Partners IV SBIC, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16884,"kind":"person","name":"INGRAM ROBERT ALEXANDER","position":4,"cik":"0001219890","reported_name":"INGRAM ROBERT ALEXANDER","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162814,"kind":"person","name":"Crumpler John","position":5,"cik":"0001674107","reported_name":"Crumpler John","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112297,"kind":"person","name":"LEE KENNETH B JR","position":6,"cik":"0001208570","reported_name":"LEE KENNETH B JR","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162813,"kind":"person","name":"Reed Douglas MD","position":7,"cik":"0001291262","reported_name":"Reed Douglas MD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-23T20:46:07.000Z","date":"2018-05-22","kind":"sale","acquired":false,"shares":5592,"price":50.8593,"value":284405.2056,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price represents the weighted average price with a low of $50.50 and a high of $51.25."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC (\"HVA V\"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a \"Managing Member\" and collectively, the \"Managing Members\"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Following the reported transaction, 210,798 shares of the reportable securities are owned directly by Hatteras NC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Following the reported transaction, 3,826,726 shares of the reportable securities are owned directly by HVP IV."}],"balance_after":4038519,"source":{"system":"sec-edgar","filing":"0001209191-18-032789","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1674107/000120919118032789/doc4.xml","form_type":"4"}},{"id":3920689,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":166141,"kind":"organization","name":"Hatteras Venture Advisors IV SBIC, LLC","position":2,"cik":"0001675236","reported_name":"Hatteras Venture Advisors IV SBIC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":166142,"kind":"organization","name":"Hatteras Venture Partners IV SBIC, LP","position":3,"cik":"0001675232","reported_name":"Hatteras Venture Partners IV SBIC, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16884,"kind":"person","name":"INGRAM ROBERT ALEXANDER","position":4,"cik":"0001219890","reported_name":"INGRAM ROBERT ALEXANDER","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162814,"kind":"person","name":"Crumpler John","position":5,"cik":"0001674107","reported_name":"Crumpler John","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112297,"kind":"person","name":"LEE KENNETH B JR","position":6,"cik":"0001208570","reported_name":"LEE KENNETH B JR","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162813,"kind":"person","name":"Reed Douglas MD","position":7,"cik":"0001291262","reported_name":"Reed Douglas MD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-23T20:46:07.000Z","date":"2018-05-21","kind":"sale","acquired":false,"shares":26,"price":52.13,"value":1355.38,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price represents the weighted average price with a low of $52.12 and a high of $52.14."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC (\"HVA V\"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a \"Managing Member\" and collectively, the \"Managing Members\"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Following the reported transaction, 3,832,318 shares of the reportable securities are owned directly by HVP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Following the reported transaction, 210,798 shares of the reportable securities are owned directly by Hatteras NC."}],"balance_after":4044111,"source":{"system":"sec-edgar","filing":"0001209191-18-032789","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1674107/000120919118032789/doc4.xml","form_type":"4"}},{"id":3920688,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":166141,"kind":"organization","name":"Hatteras Venture Advisors IV SBIC, LLC","position":2,"cik":"0001675236","reported_name":"Hatteras Venture Advisors IV SBIC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":166142,"kind":"organization","name":"Hatteras Venture Partners IV SBIC, LP","position":3,"cik":"0001675232","reported_name":"Hatteras Venture Partners IV SBIC, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16884,"kind":"person","name":"INGRAM ROBERT ALEXANDER","position":4,"cik":"0001219890","reported_name":"INGRAM ROBERT ALEXANDER","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162814,"kind":"person","name":"Crumpler John","position":5,"cik":"0001674107","reported_name":"Crumpler John","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112297,"kind":"person","name":"LEE KENNETH B JR","position":6,"cik":"0001208570","reported_name":"LEE KENNETH B JR","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162813,"kind":"person","name":"Reed Douglas MD","position":7,"cik":"0001291262","reported_name":"Reed Douglas MD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-23T20:46:07.000Z","date":"2018-05-21","kind":"sale","acquired":false,"shares":474,"price":52.13,"value":24709.62,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price represents the weighted average price with a low of $52.12 and a high of $52.14."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC (\"HVA V\"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a \"Managing Member\" and collectively, the \"Managing Members\"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Following the reported transaction, 210,824 shares of the reportable securities are owned directly by Hatteras NC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Following the reported transaction, 3,832,318 shares of the reportable securities are owned directly by HVP IV."}],"balance_after":4044137,"source":{"system":"sec-edgar","filing":"0001209191-18-032789","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674107/000120919118032789/doc4.xml","form_type":"4"}},{"id":3920687,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":166141,"kind":"organization","name":"Hatteras Venture Advisors IV SBIC, LLC","position":2,"cik":"0001675236","reported_name":"Hatteras Venture Advisors IV SBIC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":166142,"kind":"organization","name":"Hatteras Venture Partners IV SBIC, LP","position":3,"cik":"0001675232","reported_name":"Hatteras Venture Partners IV SBIC, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16884,"kind":"person","name":"INGRAM ROBERT ALEXANDER","position":4,"cik":"0001219890","reported_name":"INGRAM ROBERT ALEXANDER","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162814,"kind":"person","name":"Crumpler John","position":5,"cik":"0001674107","reported_name":"Crumpler John","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112297,"kind":"person","name":"LEE KENNETH B JR","position":6,"cik":"0001208570","reported_name":"LEE KENNETH B JR","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162813,"kind":"person","name":"Reed Douglas MD","position":7,"cik":"0001291262","reported_name":"Reed Douglas MD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-23T20:46:07.000Z","date":"2018-05-21","kind":"sale","acquired":false,"shares":1595,"price":51.0589,"value":81438.9455,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price represents the weighted average price with a low of $51.00 and a high of $51.755. The Reporting Persons undertake to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Following the reported transaction, 3,832,792 shares of the reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP (\"HVP IV\"). Hatteras Venture Advisors IV SBIC, LLC (\"HVA IV SBIC\") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a \"GP Managing Member\" and collectively, the \"GP Managing Members\"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC (\"HVA V\"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a \"Managing Member\" and collectively, the \"Managing Members\"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Following the reported transaction, 210,824 shares of the reportable securities are owned directly by Hatteras NC."}],"balance_after":4044611,"source":{"system":"sec-edgar","filing":"0001209191-18-032789","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674107/000120919118032789/doc4.xml","form_type":"4"}},{"id":3920686,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":166141,"kind":"organization","name":"Hatteras Venture Advisors IV SBIC, LLC","position":2,"cik":"0001675236","reported_name":"Hatteras Venture Advisors IV SBIC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":166142,"kind":"organization","name":"Hatteras Venture Partners IV SBIC, LP","position":3,"cik":"0001675232","reported_name":"Hatteras Venture Partners IV SBIC, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16884,"kind":"person","name":"INGRAM ROBERT ALEXANDER","position":4,"cik":"0001219890","reported_name":"INGRAM ROBERT ALEXANDER","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162814,"kind":"person","name":"Crumpler John","position":5,"cik":"0001674107","reported_name":"Crumpler John","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":112297,"kind":"person","name":"LEE KENNETH B JR","position":6,"cik":"0001208570","reported_name":"LEE KENNETH B JR","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162813,"kind":"person","name":"Reed Douglas MD","position":7,"cik":"0001291262","reported_name":"Reed Douglas MD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-23T20:46:07.000Z","date":"2018-05-21","kind":"sale","acquired":false,"shares":29005,"price":51.1604,"value":1483907.402,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price represents the weighted average price with a low of $51.00 and a high of $51.755. The Reporting Persons undertake to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Following the reported transaction, 3,832,792 shares of the reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP (\"HVP IV\"). Hatteras Venture Advisors IV SBIC, LLC (\"HVA IV SBIC\") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a \"GP Managing Member\" and collectively, the \"GP Managing Members\"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Following the reported transaction, 212,419 shares of the reportable securities are owned directly by Hatteras NC Fund, LP (\"Hatteras NC\"). Hatteras Venture Advisors IV, LLC (\"HVA IV\") is the general partner of Hatteras NC Fund, LP. The securities directly held by Hatteras NC are indirectly held by the individual managing members of HVA IV (each, a \"HVA IV Managing Member\" and collectively, the \"HVA IV Managing Members\"). The HVA IV Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The HVA IV Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each HVA IV Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any HVA IV Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC (\"HVA V\"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a \"Managing Member\" and collectively, the \"Managing Members\"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein."}],"balance_after":4046206,"source":{"system":"sec-edgar","filing":"0001209191-18-032789","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674107/000120919118032789/doc4.xml","form_type":"4"}},{"id":3923570,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-21T20:05:21.000Z","date":"2018-05-18","kind":"sale","acquired":false,"shares":61139,"price":13.16,"value":804589.24,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Consists of (i) 1,737 shares sold by Hatteras NC, (ii) 23,497 shares sold by HVP III, (iii) 2,108 shares sold by HVA III, (iv) 3,791 shares sold by HVP IV and (v) 30,006 shares sold by HVP IV SBIC."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This transaction was executed in multiple trades at prices ranging from $12.97 to $13.41, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of HVP IV and Hatteras NC. HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":3466394,"source":{"system":"sec-edgar","filing":"0001209191-18-031802","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1539029/000120919118031802/doc4.xml","form_type":"4"}},{"id":3923569,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-21T20:05:21.000Z","date":"2018-05-17","kind":"sale","acquired":false,"shares":100000,"price":13.03,"value":1303000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of (i) 3,000 shares sold by Hatteras NC Fund, LP (\"Hatteras NC\"), (ii) 38,300 shares sold by Hatteras Venture Partners III, LP (\"HVP III\"), (iii) 3,500 shares sold by Hatteras Venture Affiliates III, LP (\"HVA III\"), (iv) 6,200 shares sold by Hatteras Venture Partners IV, LP (\"HVP IV\") and (v) 49,000 shares sold by Hatteras Venture Partners IV SBIC, LP (\"HVP IV SBIC\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $12.23 to $13.37, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of HVP IV and Hatteras NC. HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":3527533,"source":{"system":"sec-edgar","filing":"0001209191-18-031802","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1539029/000120919118031802/doc4.xml","form_type":"4"}},{"id":3983677,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-03-23T21:51:13.000Z","date":"2018-03-23","kind":"sale","acquired":false,"shares":5231,"price":12.02,"value":62876.62,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F7","text":"Consists of (i) 154 shares sold by Hatteras NC, (ii) 2,006 shares sold by HVP III, (iii) 182 shares sold by HVA III, (iv) 324 shares sold by HVP IV and (v) 2,565 shares sold by HVP IV SBIC."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"This transaction was executed in multiple trades at prices ranging from $12.00 to $12.10, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of HVP IV and Hatteras NC. HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":3627533,"source":{"system":"sec-edgar","filing":"0001209191-18-021497","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1539029/000120919118021497/doc4.xml","form_type":"4"}},{"id":3983676,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-03-23T21:51:13.000Z","date":"2018-03-22","kind":"sale","acquired":false,"shares":33630,"price":12.07,"value":405914.1,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Consists of (i) 989 shares sold by Hatteras NC, (ii) 12,897 shares sold by HVP III, (iii) 1,170 shares sold by HVA III, (iv) 2,085 shares sold by HVP IV and (v) 16,489 shares sold by HVP IV SBIC."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This transaction was executed in multiple trades at prices ranging from $12.00 to $12.21, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of HVP IV and Hatteras NC. HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":3632764,"source":{"system":"sec-edgar","filing":"0001209191-18-021497","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1539029/000120919118021497/doc4.xml","form_type":"4"}},{"id":3983675,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-03-23T21:51:13.000Z","date":"2018-03-21","kind":"sale","acquired":false,"shares":100000,"price":12.27,"value":1227000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of (i) 2,940 shares sold by Hatteras NC Fund, LP (\"Hatteras NC\"), (ii) 38,350 shares sold by Hatteras Venture Partners III, LP (\"HVP III\"), (iii) 3,480 shares sold by Hatteras Venture Affiliates III, LP (\"HVA III\"), (iv) 6,200 shares sold by Hatteras Venture Partners IV, LP (\"HVP IV\") and (v) 49,030 shares sold by Hatteras Venture Partners IV SBIC, LP (\"HVP IV SBIC\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $12.00 to $12.49, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of HVP IV and Hatteras NC. HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":3666394,"source":{"system":"sec-edgar","filing":"0001209191-18-021497","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1539029/000120919118021497/doc4.xml","form_type":"4"}},{"id":4138986,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-07T22:10:11.000Z","date":"2017-12-07","kind":"sale","acquired":false,"shares":5000,"price":6.13,"value":30650.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holders of the securities on June 12, 2017."},{"field":"shares","element":"transactionShares","label":"F8","text":"Consists of (i) 4,584 shares sold by HVP III and (ii) 416 shares sold by HVA III."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"This transaction was executed in multiple trades at prices ranging from $5.85 to $6.35, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of Hatteras Venture Partners IV SBIC, LP; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of Hatteras Venture Partners IV, LP and Hatteras NC Fund, LP. HVP III, HVA III, Hatteras Venture Partners IV SBIC, LP, Hatteras Venture Partners IV, LP and Hatteras NC Fund, LP are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, Hatteras Venture Partners IV SBIC, LP, Hatteras Venture Partners IV, LP and Hatteras NC Fund, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":3766394,"source":{"system":"sec-edgar","filing":"0001209191-17-064491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1539029/000120919117064491/doc4.xml","form_type":"4"}},{"id":4138985,"issuer":{"id":82875,"kind":"organization","name":"Clearside Biomedical, Inc.","symbol":"CLSD"},"owners":[{"id":82876,"kind":"person","name":"Thorp Clay","position":1,"cik":"0001592380","reported_name":"Thorp Clay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-07T22:10:11.000Z","date":"2017-12-06","kind":"sale","acquired":false,"shares":15000,"price":6.09,"value":91350.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holders of the securities on June 12, 2017."},{"field":"shares","element":"transactionShares","label":"F6","text":"Consists of (i) 13,751 shares sold by HVP III and (ii) 1,249 shares sold by HVA III."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"This transaction was executed in multiple trades at prices ranging from $5.93 to $6.26, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of Hatteras Venture Partners IV SBIC, LP; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of Hatteras Venture Partners IV, LP and Hatteras NC Fund, LP. HVP III, HVA III, Hatteras Venture Partners IV SBIC, LP, Hatteras Venture Partners IV, LP and Hatteras NC Fund, LP are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, Hatteras Venture Partners IV SBIC, LP, Hatteras Venture Partners IV, LP and Hatteras NC Fund, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein."}],"balance_after":3771394,"source":{"system":"sec-edgar","filing":"0001209191-17-064491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1539029/000120919117064491/doc4.xml","form_type":"4"}}],"next_cursor":"2017-12-07T22:10:11.000000Z,4138985"}